Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported tax-driven sales of common stock. On July 2, 2026, he sold a total of 5,599 shares of Arteris common stock in multiple open-market transactions at $38.7779 per share.
According to the footnote, these sales were executed solely to satisfy his tax liability from the release of restricted stock units under the company’s equity incentive plans. The transactions were mandated "sell to cover" trades and are described as non-discretionary for the reporting person.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported selling 3,648 shares of common stock on July 2, 2026 in four open-market transactions at a price of $38.7779 per share.
According to the filing, these sales were made to satisfy the reporting person's tax liability from the release of restricted stock units and were mandated under the company’s equity incentive plans as "sell to cover" transactions, meaning they were not discretionary trades.
Arteris, Inc. VP and CFO Nicholas B. Hawkins reported routine tax-related share sales. On July 2, 2026, he sold a total of 5,377 shares of Arteris common stock in multiple open-market transactions at $38.7779 per share.
According to the footnote, these transactions were mandated "sell to cover" sales to satisfy tax liabilities from the release of restricted stock units under the company’s equity incentive plans, and are described as non-discretionary. After these sales, Hawkins directly owned 103,172 shares of Arteris common stock.
Company AIP notice of proposed sale of common stock by an insider. The filing lists 6003 shares of Common stock from Restricted Stock Units with an effective date of 07/01/2026. It also discloses recent 10b5-1 sales by Paul Lawrence Alpern of 6,500 shares on 07/01/2026 and 12,502 shares on 06/01/2026, with proceeds shown in the excerpt.
BAYVIEW LEGACY, LLC reported proposed sales of Common Stock of AIP under Rule 144 via 10b5-1 arrangements. The notice lists 181,338 shares on 07/01/2026 with proceeds of $8,243,335.34 and 192,686 shares on 07/02/2026 with proceeds of $6,998,663.82. The broker shown is Morgan Stanley Smith Barney LLC.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported multiple transactions in the company’s common stock on July 1, 2026. He sold a total of 6,500 shares in open-market transactions at weighted average prices ranging from about $43.70 to $47.50, carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026. On the same date, he exercised stock options to acquire 6,500 shares of common stock at exercise prices of $9.28 and $0.56 per share. Following these transactions, he continues to hold more than 80,000 shares of Arteris common stock directly.
Arteris, Inc. director and CEO K. Charles Janac reported indirect open-market sales of 181,338 shares of Arteris common stock on July 1, 2026 through Bayview Legacy, LLC, where he serves as manager. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, at weighted-average prices reported between $44.0606 and $47.0752 per share.
Following these transactions, Bayview Legacy, LLC beneficially owned 8,747,733 shares of Arteris common stock indirectly attributed to Janac. Separate holding entries show an additional 196,729 shares held directly and 56,252 shares held through the Charles and Lydia Janac Trust.
Arteris, Inc. major holder Bayview Legacy, LLC reported selling common stock in multiple open-market transactions. On July 1, 2026, Bayview executed four sales totaling 181,338 shares of Arteris common stock at weighted average prices between $44.0606 and $47.0752.
The trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by K. Charles Janac, who manages Bayview Legacy, LLC and is deemed to have voting and dispositive power over the shares.
Arteris, Inc. director Saiyed Atiq Raza reported significant insider sales of Arteris (AIP) common stock. On 2026-07-01, a revocable trust for which he serves as trustee sold an aggregate of 70,000 shares in multiple open-market transactions at weighted-average prices including $47.1004, $44.9884, $43.9796 and $46.1987 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the sales, the trust held 119,041 shares of common stock, and Raza also held 4,703 shares directly.
Bayview Legacy, LLC reported proposed resale of 700,000 shares of Common Stock, acquired 11/05/2013, on Nasdaq. The filing lists recent automated sales executed under a 10b5-1 plan: 70,000 shares sold on each of 04/08/2026, 05/08/2026, and 06/08/2026, with proceeds of $1,332,782, $2,183,986, and $2,443,434, respectively.
Shares outstanding are shown as 46,171,982 as of 07/01/2026. The resale is described as a private acquisition from the issuer or an affiliate, and transactions were effected pursuant to a 10b5-1 plan per the sales entries.